Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33678 NOVABAY PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 68-045 ...

Financial Data and Key Metrics Changes - Net product revenue for Q2 2023 was $4.6 million, a 26% increase from the prior year quarter, driven by record sales of wound care products [16][28] - Operating loss for the quarter was $1.4 million, a 37% improvement from the prior year [17] - Gross margin on net product revenue remained consistent at 50% for both Q2 2023 and Q2 2022 [16] - Cash and cash equivalents were reported at $4.4 million as of June 30, 2023, including proceeds from a $3 million private placement [18] Business Line Data and Key Metrics Changes - Avenova branded product sales amounted to $2.2 million, while DERMAdoctor product sales reached $1.1 million, and branded wound care products generated $1.3 million in sales [16] - Sales of DERMAdoctor products increased to $1.1 million for the quarter, up more than 40% versus the prior year, with notable contributions from international markets [7] Market Data and Key Metrics Changes - Avenova products achieved record sales during Amazon Prime Day, with a 22% increase over Prime Day 2022 and a 43% increase over Prime Day 2021 [30] - The physician dispense channel showed momentum, representing a win-win for the company and eye care specialists [29] Company Strategy and Development Direction - The company is shifting its focus in the DERMAdoctor line away from new product development to increasing sales of top-selling products through efficient sales channels [12] - The strategy aims for profitability by managing expenses and extending cash runway while focusing on proven products [20][32] Management's Comments on Operating Environment and Future Outlook - Management anticipates incremental growth in the eye care segment for the remainder of 2023, particularly through online sales channels [31] - The company is leveraging its digital marketing expertise to effectively promote products while managing expenditures [38] Other Important Information - Total operating expenses for Q2 2023 decreased by 8% over the prior year, including a 16% reduction in sales and marketing expenses [36] - The gross margin on net product sales increased to 55% for the first half of 2023 compared to 53% for the first half of 2022 [37] Q&A Session Summary Question: What was the actual cash loss for the second quarter? - The actual cash loss for the second quarter was about $1 million [22] Question: Can you discuss the wound business, specifically channels and SKUs? - The wound care segment consists of only two products, PhaseOne and NeutroPhase, with two sizes each [22] Question: What are the DERMAdoctor channels besides the direct website and Amazon? - The main sales channels include Amazon, dermadoctor.com, Costco, and international markets like the Middle East and China [23] Question: Any insights on margin expectations for the back half of the year? - Margins are expected to be around 55%, with slight increases due to the lower margin of wound care products [40]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33678 NOVABAY PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 68-0454536 ...

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Jody Cain - LHA, IR Justin Hall - Chief Executive Officer and General Counsel Tommy Law - Interim Chief Financial Officer Conference Call Participants Anderson Schock - Ladenburg Thalmann Operator Welcome to the NovaBay Pharmaceuticals First Quarter 2023 Financial Results Conference Call. At this time, all participants are in listen-only mode. Following management’s prepared remarks, we wil ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33678 NOVABAY PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 68-0454536 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33678 NOVABAY PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdic ...

Financial Data and Key Metrics Changes - The net product revenue for the fourth quarter of 2022 increased 15% year-over-year to $3.6 million, including $2.1 million from Avenova, $1 million from DERMAdoctor, and $0.4 million from wound care products [47] - For the full year 2022, product revenue was $14.4 million, a 41% increase over 2021, reflecting a full year of DERMAdoctor product sales [21] - The net loss attributable to common stockholders for Q4 2022 was $8.2 million or $0.433 per share, which included a large non-cash impairment charge of $6.7 million [48] Business Line Data and Key Metrics Changes - Avenova continues to be the highest revenue driver and highest gross margin product, with sales of companion products growing steadily [17] - The introduction of Eyeganics Organic Tears, a USDA certified organic eye drop, adds to the eye care portfolio [3] - DERMAdoctor's new KP Duty peel pads were introduced, focusing on customer loyalty and attracting new users [4] Market Data and Key Metrics Changes - The global market for dry eye is expected to reach nearly $9 billion by 2030, with 49 million Americans suffering from dry eyes [2] - The company is focusing on international growth opportunities, particularly in China and the EU for DERMAdoctor products [29] Company Strategy and Development Direction - The company aims to leverage relationships with eye care professionals to enhance the Avenova brand and expand its customer base [27] - A shift in strategy for 2023 focuses on selling existing products more effectively rather than launching new ones [38] - The company plans to expand its eye care portfolio with additional innovative products for dry eye and other ophthalmic conditions [45] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the impact of external factors like the COVID-19 pandemic and geopolitical tensions on operations and financial results [1] - The company expects continued growth in the wound care sector and aims to optimize digital marketing efforts [25][31] Other Important Information - The company completed the acquisition of DERMAdoctor in November 2021, and the financial results reflect operations post-acquisition [5] - R&D expenses for 2022 were $174,000, significantly higher than $44,000 in the prior year, indicating increased investment in product development [6] Q&A Session Summary Question: Can you discuss Q4 margins and expectations for 2023? - Management noted that lower margins in Q4 were due to higher sales of lower-margin products, but Avenova's margins remain strong. Future margins will depend on product mix [25] Question: What is the company's approach to M&A? - The company is committed to pursuing M&A opportunities, particularly in the eye care vertical, and aims to leverage existing relationships with eye care professionals [54] Question: What are the expectations for international growth? - The company sees significant growth opportunities in China and the EU for DERMAdoctor products and plans to align distributors to support this growth [29]

Financial Data and Key Metrics Changes - Product revenue for Q3 2022 was $3.8 million, a 69% increase from the prior year period, driven by the acquisition of DERMAdoctor and diversified revenue streams [5][26] - Gross margin for Q3 2022 was 62%, down from 69% in Q3 2021, primarily due to the addition of DERMAdoctor and wound care product sales [27] - Net loss attributable to common stockholders for Q3 2022 was $5.8 million or $0.10 per share, compared to a net loss of $2.3 million or $0.05 per share in Q3 2021 [31] Business Line Data and Key Metrics Changes - Avenova spray sales for Q3 2022 were $1.9 million, down from $2.1 million a year ago, attributed to a shift to a more efficient online sales channel [26] - DERMAdoctor product sales reached $1.3 million in Q3 2022, marking the highest sales quarter since the acquisition [26] - Sales and marketing expenses decreased by 11% to $1.8 million, despite the addition of DERMAdoctor sales and marketing costs [28] Market Data and Key Metrics Changes - The company reported that more than two-thirds of Avenova unit sales were generated online, indicating a successful shift to digital marketing [7][8] - The skincare eCommerce market in the US is projected to reach $18 billion in 2022, with significant growth expected in the coming years [11] - The company is expanding its presence in international markets, particularly in China and Europe, with a focus on increasing brand awareness [15][16] Company Strategy and Development Direction - The company aims to capitalize on established brands in eye care, skin care, and wound care, with plans to introduce new products and expand digital marketing efforts [34] - Increasing DERMAdoctor's presence in international markets is a key priority, leveraging strong local partnerships for market penetration [14][15] - The company is focused on optimizing marketing tactics and expanding target demographics to drive sales growth [40][42] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued growth, particularly in online sales and international markets [5][34] - The company acknowledged potential risks from external factors such as the COVID-19 pandemic and geopolitical tensions [4] - Management highlighted the importance of adapting marketing strategies to reach new demographics, particularly younger consumers for Avenova [42] Other Important Information - The company held a special meeting of stockholders, approving a one-for-thirty-five reverse stock split to regain compliance with NYSE listing requirements [20][21] - The company reported cash and cash equivalents of $3.9 million as of September 30, 2022, including proceeds from a warrant reprice transaction [33] Q&A Session Summary Question: Inquiry about marketing expense reduction - Management confirmed that the 11% decrease in sales and marketing expenses was due to improved digital marketing tactics, cross-selling, and upselling opportunities [39][40] Question: Expansion of demographic targeting - Management indicated that Avenova is targeting a younger demographic due to the prevalence of dry eye issues among younger consumers, while DERMAdoctor is expanding into new geographic territories [42][43] Question: Commercialization process in Europe - Management stated that they are onboarding a partner to serve as the main distributor for the European Union, with potential revenue expected in early 2023 [45][46] Question: Impact of lower margins - Management explained that lower margins were primarily due to the addition of DERMAdoctor products and increased wound care sales, which generally have lower margins [47][49]

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Justin Hall - Chief Executive Officer and General Counsel Andy Jones - Chief Financial Officer Kim Shartsis - Vice President of Commercial Conference Call Participants Operator Welcome to the NovaBay Pharmaceuticals Second Quarter 2020 Financial Results Conference Call. At this time, all participants are in listen-only-mode. Following management's prepa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33678 NOVABAY PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 68-0454536 ...